<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Russian Journal of Pediatric Surgery, Anesthesia and Intensive Care</journal-id><journal-title-group><journal-title xml:lang="en">Russian Journal of Pediatric Surgery, Anesthesia and Intensive Care</journal-title><trans-title-group xml:lang="ru"><trans-title>Российский вестник детской хирургии, анестезиологии и реаниматологии</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2219-4061</issn><issn publication-format="electronic">2587-6554</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1844</article-id><article-id pub-id-type="doi">10.17816/psaic1844</article-id><article-id pub-id-type="edn">TSLHBO</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Original Study Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Оригинальные исследования</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Surgical Treatment of Children with Neurofibromatosis Type 1: a Case Series</article-title><trans-title-group xml:lang="ru"><trans-title>Хирургическое лечение детей с нейрофиброматозом 1-го типа: серия случаев</trans-title></trans-title-group><trans-title-group xml:lang="zh"><trans-title>1型神经纤维瘤病患儿的外科治疗：病例系列</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8868-4763</contrib-id><contrib-id contrib-id-type="spin">2881-3415</contrib-id><name-alternatives><name xml:lang="en"><surname>Sukhodolskaya</surname><given-names>Olga V.</given-names></name><name xml:lang="ru"><surname>Суходольская</surname><given-names>Ольга Владимировна</given-names></name><name xml:lang="zh"><surname>Sukhodolskaya</surname><given-names>Olga V.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>betti_olga99@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7879-315X</contrib-id><contrib-id contrib-id-type="spin">5156-1745</contrib-id><name-alternatives><name xml:lang="en"><surname>Dorofeeva</surname><given-names>Marina Yu.</given-names></name><name xml:lang="ru"><surname>Дорофеева</surname><given-names>Марина Юрьевна</given-names></name><name xml:lang="zh"><surname>Dorofeeva</surname><given-names>Marina Yu.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Cand. Sci. (Medicine)</p></bio><bio xml:lang="ru"><p>канд. мед. наук</p></bio><bio xml:lang="zh"><p>MD, Cand. Sci. (Medicine)</p></bio><email>mdorofeeva@inbox.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7291-5459</contrib-id><contrib-id contrib-id-type="spin">6584-4201</contrib-id><name-alternatives><name xml:lang="en"><surname>Bochenkov</surname><given-names>Sergey V.</given-names></name><name xml:lang="ru"><surname>Боченков</surname><given-names>Сергей Викторович</given-names></name><name xml:lang="zh"><surname>Bochenkov</surname><given-names>Sergey V.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>boch@pedklin.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7520-1072</contrib-id><contrib-id contrib-id-type="spin">2754-6879</contrib-id><name-alternatives><name xml:lang="en"><surname>Pivovarova</surname><given-names>Alexandra M.</given-names></name><name xml:lang="ru"><surname>Пивоварова</surname><given-names>Александра Михайловна</given-names></name><name xml:lang="zh"><surname>Pivovarova</surname><given-names>Alexandra M.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Cand. Sci. (Medicine)</p></bio><bio xml:lang="ru"><p>канд. мед. наук</p></bio><bio xml:lang="zh"><p>MD, Cand. Sci. (Medicine)</p></bio><email>ampivovarova@gmail.com</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4816-9369</contrib-id><contrib-id contrib-id-type="spin">8382-4911</contrib-id><name-alternatives><name xml:lang="en"><surname>Zabrodina</surname><given-names>Anna R.</given-names></name><name xml:lang="ru"><surname>Забродина</surname><given-names>Анна Романовна</given-names></name><name xml:lang="zh"><surname>Zabrodina</surname><given-names>Anna R.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>zabrodina@pedklin.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1105-9679</contrib-id><name-alternatives><name xml:lang="en"><surname>Jivanshiryan</surname><given-names>Goar V.</given-names></name><name xml:lang="ru"><surname>Дживанширян</surname><given-names>Гоар Владимировна</given-names></name><name xml:lang="zh"><surname>Jivanshiryan</surname><given-names>Goar V.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>Dzhivanshiryan.g@pedklin.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2387-8740</contrib-id><contrib-id contrib-id-type="spin">2175-3280</contrib-id><name-alternatives><name xml:lang="en"><surname>Tarasova</surname><given-names>Daria S.</given-names></name><name xml:lang="ru"><surname>Тарасова</surname><given-names>Дарья Сергеевна</given-names></name><name xml:lang="zh"><surname>Tarasova</surname><given-names>Daria S.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Cand. Sci. (Medicine)</p></bio><bio xml:lang="ru"><p>канд. мед. наук</p></bio><bio xml:lang="zh"><p>MD, Cand. Sci. (Medicine)</p></bio><email>dtarasowa@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0348-929X</contrib-id><contrib-id contrib-id-type="spin">3683-7312</contrib-id><name-alternatives><name xml:lang="en"><surname>Ayrapetyan</surname><given-names>Maxim I.</given-names></name><name xml:lang="ru"><surname>Айрапетян</surname><given-names>Максим Игоревич</given-names></name><name xml:lang="zh"><surname>Ayrapetyan</surname><given-names>Maxim I.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Cand. Sci. (Medicine), Associate Professor</p></bio><bio xml:lang="ru"><p>канд. мед. наук, доцент</p></bio><bio xml:lang="zh"><p>MD, Cand. Sci. (Medicine), Associate Professor</p></bio><email>Drairmaxim@gmail.com</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1940-1395</contrib-id><contrib-id contrib-id-type="spin">8779-8960</contrib-id><name-alternatives><name xml:lang="en"><surname>Morozov</surname><given-names>Dmitry A.</given-names></name><name xml:lang="ru"><surname>Морозов</surname><given-names>Дмитрий Анатольевич</given-names></name><name xml:lang="zh"><surname>Morozov</surname><given-names>Dmitry A.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Medicine), Professor</p></bio><bio xml:lang="ru"><p>д-р мед. наук, профессор</p></bio><bio xml:lang="zh"><p>MD, Dr. Sci. (Medicine), Professor</p></bio><email>damorozov@list.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Sechenov First Moscow State Medical University</institution></aff><aff><institution xml:lang="ru">Первый Московский государственный медицинский университет им. И.М. Сеченова</institution></aff><aff><institution xml:lang="zh">Sechenov First Moscow State Medical University</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Pirogov Russian National Research Medical University</institution></aff><aff><institution xml:lang="ru">Российский национальный исследовательский медицинский университет им. Н.И. Пирогова</institution></aff><aff><institution xml:lang="zh">Pirogov Russian National Research Medical University</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2025-07-15" publication-format="electronic"><day>15</day><month>07</month><year>2025</year></pub-date><volume>15</volume><issue>2</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><issue-title xml:lang="zh"/><fpage>181</fpage><lpage>192</lpage><history><date date-type="received" iso-8601-date="2024-11-18"><day>18</day><month>11</month><year>2024</year></date><date date-type="accepted" iso-8601-date="2025-05-26"><day>26</day><month>05</month><year>2025</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2025, Eco-Vector</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2025, Эко-Вектор</copyright-statement><copyright-statement xml:lang="zh">Copyright ©; 2025,</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="en">Eco-Vector</copyright-holder><copyright-holder xml:lang="ru">Эко-Вектор</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-nd/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://rps-journal.ru/jour/article/view/1844">https://rps-journal.ru/jour/article/view/1844</self-uri><abstract xml:lang="en"><p><bold>BACKGROUND:</bold> Among hereditary diseases predisposing individuals to tumor development, neurofibromatosis type 1 ranks among the most prevalent. Due to the heterogeneity of clinical symptoms typical for this condition, patients often consult various specialists, which objectively leads to underestimation of symptoms and delayed diagnosis.</p> <p><bold>AIM:</bold> This study aimed to perform a comparative analysis of diagnostic approaches and surgical treatment in patients with this disease given the rarity of the disease and the lack of unified management protocols for neurofibromatosis type 1 in Russia to date.</p> <p><bold>METHODS:</bold> A retrospective analysis was conducted on clinical data from 20 pediatric patients who underwent surgical treatment for neurofibromatosis type 1 at the Yu.E. Veltishchev Research Clinical Institute of Pediatrics and Pediatric Surgery.</p> <p><bold>RESULTS:</bold> Clinical records of 20 children (9 boys and 11 girls) were reviewed. The median age at the time of diagnosis was 7 years (1 to 17 years). In most patients (<italic>n</italic> = 15), neurofibromatosis type 1 manifestations were located in the head and neck region. The absence of a standardized diagnostic protocol for children with suspected neurofibromatosis was noted: magnetic resonance imaging of the affected area was performed in 19 patients, whereas brain magnetic resonance imaging and abdominal ultrasound were conducted in only one-third of the patients. In total, 36 surgeries were performed. The presence of a mass was the indication for surgery in 20 cases. In 3 patients with neurofibromas, initial histological diagnosis was incorrect, resulting in delayed diagnosis and inappropriate treatment strategies. Tumor recurrence was observed in 14 of the 26 cases following complete excision, which necessitated repeat surgical interventions (<italic>n</italic> = 9). A rare case of intestinal ganglioneurofibromatosis is also presented.</p> <p><bold>CONCLUSION:</bold> Variability in clinical manifestations, the rarity of the condition, and a general lack of awareness among pediatric surgeons often result in delayed diagnosis and inadequate treatment. Children were assessed and managed by various specialists without a systematic approach, and often underwent surgery without consideration of the pathogenesis of their condition. The creation of a clinical registry for such patients, as well as the establishment of multidisciplinary medical teams, with treatment decisions for children with neurofibromatosis type 1 made exclusively through case conferences, is of great importance.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Обоснование.</bold> Среди наследственных заболеваний, предопределяющих возникновение в организме человека опухолей, нейрофиброматоз 1-го типа занимает лидирующее место. Из-за гетерогенности клинических симптомов, характерных для данного заболевания, пациенты обращаются к разным специалистам, что объективно приводит к недооценке симптомов и несвоевременной диагностике заболевания.</p> <p><bold>Цель</bold> — учитывая редкость патологии и отсутствие до настоящего времени в нашей стране единых протоколов ведения пациентов с нейрофиброматозом 1-го типа, провести сравнительный анализ диагностики и хирургического лечения пациентов с этим заболеванием.</p> <p><bold>Материалы и методы.</bold> Ретроспективно проанализированы клинические данные 20 детей, которым было проведено хирургическое лечение по поводу нейрофиброматоза 1-го типа, наблюдавшихся в Научно-исследовательском клиническом институте педиатрии и детской хирургии им. акад. Ю.Е. Вельтищева.</p> <p><bold>Результаты.</bold> Было изучено 20 историй болезни (9 мальчиков и 11 девочек). Медиана возраста постановки диагноза составила 7 лет (1–17 лет). У большинства пациентов (<italic>n</italic> = 15) проявления нейрофиброматоза 1-го типа затрагивали область головы/шеи. Обращено внимание на отсутствие единого протокола исследования детей с подозрением на нейрофиброматоз: 19 пациентам выполнена магнитно-резонансная томография пораженной области, а магнитно-резонансная томография головного мозга и ультразвуковое исследование органов брюшной полости были выполнены только у трети пациентов. Всего было проведено 36 операций. Показанием к оперативному лечению в 20 случаях стало наличие объемного образования. У 3 пациентов с нейрофибромами первичное гистологическое заключение было ошибочным, что привело к несвоевременной постановке диагноза и неправильной тактике. Рецидивы роста опухолей были отмечены в 14 из 26 случаев полного их удаления, что потребовало выполнения повторных оперативных вмешательств (<italic>n</italic> = 9). В статье представлено редкое клиническое наблюдение ганглионейрофиброматоза кишечника.</p> <p><bold>Заключение.</bold> Вариабельность клинических проявлений и редкость патологии, отсутствие настороженности детских хирургов в отношении данного заболевания зачастую приводили к несвоевременной диагностике и некорректному лечению. Дети наблюдались и обследовались у разных специалистов без системного подхода, часто получая хирургическое лечение без учета особенностей патогенеза их заболевания. Важным является создание клинического реестра таких пациентов, а также мультидисциплинарных команд врачей, принятие решения о выборе тактики лечения детей с нейрофиброматозом 1-го типа исключительно посредством консилиума.</p></trans-abstract><trans-abstract xml:lang="zh"><p><bold>论证。</bold>在决定人体内肿瘤发生倾向的遗传性疾病中，1型神经纤维瘤病处于主导地位。由于该病具有临床症状异质性的特点，患者常被不同专科医生接诊，从而客观上导致症状被低估和诊断延迟。</p> <p><bold>目的。</bold>鉴于该疾病的罕见性，以及目前俄罗斯尚缺乏统一的1型神经纤维瘤病患者管理方案，本文旨在对该病患者的诊断与外科治疗情况进行比较分析。</p> <p><bold>方法。</bold>回顾性分析在Research Clinical Institute of Pediatrics and Pediatric Surgery named after acad. Y.E. Veltishchev接受1型神经纤维瘤病相关外科治疗的20例患儿的临床资料。</p> <p><bold>结果。</bold>共分析20份病历资料（9例男童，11例女童）。诊断时年龄的中位数为7岁（范围1–17岁）。大多数患者（n = 15）的1型神经纤维瘤病表现累及头颈部区域。指出目前尚缺乏对疑似1型神经纤维瘤病患儿的统一检查方案：19例患者接受了病变区域的磁共振成像检查，而仅约三分之一患者同时接受了脑部磁共振成像和腹部器官超声检查。共实施了36例手术。20例患者因发现占位性病变而被建议进行手术治疗。3例神经纤维瘤患者的初始病理诊断出现误判，导致诊断延迟并采取了不恰当的治疗策略。在26例肿瘤完全切除的患者中，有14例出现复发，需再次手术治疗（n = 9）。文中还报道了一例罕见的肠道神经节神经纤维瘤病病例。</p> <p><bold>结论。</bold>该病临床表现多样且较为罕见，加之小儿外科医生对此缺乏足够警惕，常导致诊断滞后及治疗不当。患儿常由不同专科医生分别进行检查与管理，缺乏系统化策略，外科治疗亦常未充分考虑疾病的病理基础。重要的是建立此类患者的临床登记系统，并组建多学科医生团队，仅通过专家会诊决定1型神经纤维瘤病患儿的治疗策略。</p></trans-abstract><kwd-group xml:lang="en"><kwd>children</kwd><kwd>neurofibromatosis type 1</kwd><kwd>plexiform neurofibroma</kwd><kwd>surgical treatment</kwd><kwd>intestinal ganglioneurofibromatosis</kwd><kwd>case series</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>дети</kwd><kwd>нейрофиброматоз 1-го типа</kwd><kwd>плексиформная нейрофиброма</kwd><kwd>хирургическое лечение</kwd><kwd>ганглионейрофиброматоз кишечника</kwd><kwd>серия клинических наблюдений</kwd></kwd-group><kwd-group xml:lang="zh"><kwd>儿童</kwd><kwd>1型神经纤维瘤病</kwd><kwd>丛状神经纤维瘤</kwd><kwd>外科治疗</kwd><kwd>肠道神经节神经纤维瘤病</kwd><kwd>病例系列研究</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Farschtschi S, Mautner V-F, Cecilia Lawson McLean A, et al. The neurofibromatoses. Dtsch Arztebl Int. 2020;117:354–360. doi: 10.3238/arztebl.2020.0354</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Garozzo D. Peripheral nerve tumors in neurofibromatosis 1: An overview on management and indications for surgical treatment in our experience. Neurology India. 2019;67(S1):S38–S44. doi: 10.4103/0028-3886.250697</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Dogra BB, Rana KS. Facial plexiform neurofibromatosis: A surgical challenge. Indian Dermatol Online J. 2013;4(3):195–198. doi: 10.4103/2229-5178.115515</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Resolution of the Expert council on the problems of diagnosis and treatment of patients with plexiform neurofibromas. Russian Journal of Pediatric Hematology and Oncology. 2021;8(2):144–152. doi: 10.21682/2311-1267-2021-8-2-144-152 EDN: FAFYHA</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Blakeley JO, Plotkin SR. Therapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and schwannomatosis. Neuro Oncol. 2016;18(5):624–638. doi: 10.1093/neuonc/nov200</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Prudner BC, Ball T, Rathore R, Hirbe AC. Diagnosis and management of malignant peripheral nerve sheath tumors: Current practice and future perspectives. Neurooncol Adv. 2020;2(S1):i40–i49. doi: 10.1093/noajnl/vdz047</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Hirbe AC, Gutmann DH. Neurofibromatosis type 1: a multidisciplinary approach to care. Lancet Neurol. 2014;13(8):834–843. doi: 10.1016/S1474-4422(14)70063-8</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Legius E, Messiaen L, Wolkenstein P, et al. Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation. Genet Med. 2021;23(8):1506–1513. doi: 10.1038/s41436-021-01170-5</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Bergqvist C, Servy A, Valeyrie-Allanore L, et al. Neurofibromatosis 1 French national guidelines based on an extensive literature review since 1966. Orphanet J Rare Dis. 2020;15(1):37. doi: 10.1186/s13023-020-1310-3</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Mauro A, Zenzeri L, Esposito F, et al. Isolated intestinal Ganglioneuromatosis: case report and literature review. Ital J Pediatr. 2021;47(1):80. doi: 10.1186/s13052-021-01024-5</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Rabab’h O, Gharaibeh A, Al-Ramadan A, Ismail M, Shah J. Pharmacological approaches in neurofibromatosis type 1-associated nervous system tumors. Cancers. 2021;13(15):3880. doi: 10.3390/cancers13153880</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Bai R-Y, Esposito D, Tam AJ, et al. Feasibility of using NF1-GRD and AAV for gene replacement therapy in NF1-associated tumors. Gene Ther. 2019;26(6):277–286. doi: 10.1038/s41434-019-0080-9</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Gross AM, Wolters PL, Dombi E, et al. Selumetinib in children with inoperable plexiform neurofibromas. N Engl J Med. 2020;382(15):1430–1442. doi: 10.1056/NEJMoa1912735</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Hsieh DT, Rohena LO, Talaver F, et al. Neurofibromatosis type 1 differential diagnoses. Medscape, 2022.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Gerszten PC, Burton SA, Ozhasoglu C, et al. Radiosurgery for benign intradural spinal tumors. Neurosurgery. 2008;62(4):887–895. doi: 10.1227/01.neu.0000318174.28461.fc</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Friedrich RE, Schmelzle R, Hartmann M, et al. Resection of small plexiform neurofibromas in neurofibromatosis type 1 children. World J Surg Oncol. 2005;3(1):6. doi: 10.1186/1477-7819-3-6</mixed-citation></ref></ref-list></back></article>
